Navigation Links
Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec
Date:7/13/2009

SOUTH SAN FRANCISCO, Calif., July 13 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that it has received a $1.5 million milestone payment from Biogen Idec (Nasdaq: BIIB) for the selection of a Raf kinase inhibitor development candidate for the treatment of cancer. Biogen Idec is currently conducting IND-enabling GLP preclinical work with the Raf kinase development candidate.

"While our internal efforts are focused on the successful development of voreloxin, we are extremely pleased by the continued progress being made by Biogen Idec to advance a Raf kinase inhibitor toward the clinic," said Daniel Swisher, Sunesis' Chief Executive Officer.

In August 2004 the companies entered into a collaboration to discover and develop small molecule cancer therapeutics targeting kinases, a family of cell signaling enzymes that play a major role in the progression of cancer. The research term of this collaboration ended in June of 2008. Sunesis retains an option to participate in the co-development and co-promotion of the Raf kinase inhibitor resulting from this collaboration.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing voreloxin in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO
2. Sunesis Reports Financial Results for the First Quarter 2009
3. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
4. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
5. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
8. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Experienced dress company, Discount-Dress.com, announces that ... of trendy black bridesmaid dresses. Furthermore, the company has ... bridesmaid outfits. Readers can view more about ... is a famous brand of special occasion gowns ... well as revamped old editions, the supplier has set ...
(Date:9/17/2014)... 2014 Headquartered in Baltimore, Maryland, ... across the country. , “The past two weeks ... have grown to over 400 evaluators in 46 states, ... in the Midwest and South Dakota and Vermont. And ... where our volunteers can visit.” , TPU provides one-of-a-kind ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Request A ... lab testing, is offering 10% off drug testing ... to all drug tests, including those ordered by employers for ... take advantage of this discount by using promo code DRUG10 ... increase in positives on workplace drug testing, especially for marijuana ...
(Date:9/17/2014)... New York (PRWEB) September 17, 2014 ... together with experienced coaches to complete a three stage ... Adventure Team Challenge New York . , Hosted ... York’s Catskill Mountains, the 2014 Challenge includes five participating ... coaches for each athlete with disabilities will provide expert ...
(Date:9/17/2014)... 17, 2014 ICS Learning Group, Inc. ... Excellence in Training for the Best Use of Games ... on an online operational safety training module that ICS ... operation. Using an approach that combined realistic 3D ... that was similar to a video game, including competition ...
Breaking Medicine News(10 mins):Health News:Discount-Dress.com’s Top Designers Are Now Busy Making Its New Black Bridesmaid Dresses 2Health News:Therapy Pets Unlimited is Expanding 2Health News:Therapy Pets Unlimited is Expanding 3Health News:Request A Test Can Save You 10% on Drug Testing 2Health News:Request A Test Can Save You 10% on Drug Testing 3Health News:World T.E.A.M. Sports’ Adventure Team Challenge New York Includes Disabled Athletes 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge New York Includes Disabled Athletes 3Health News:ICS Learning Group Wins Gold in the 2014 Brandon Hall Excellence Competition for Best Use of Games and Simulations for Learning 2
... As the connection between second-hand smoke and coronary heart ... reduce such passive smoking, exposures have been reduced. In ... the American Journal of Preventive Medicine , researchers ... Boston and Columbia University have recalibrated the CHD Policy ...
... Prior Year Quarter --, ... ... , TSX Venture Exchange: NVC , , ... specialty vascular device company, today announced financial results for the third quarter and ...
... - The Westaim Corporation today announced it has requisitioned ... to consider a return of capital to NUCRYST shareholders ... will continue to review alternatives to maximize the value ... the Alberta Business Corporations Act, NUCRYST,s Board of Directors ...
... nicotine use, personality illnesses common, study shows , , ... common among young adults in the United States, but ... reach this finding, U.S. researchers analyzed data from more ... part in the National Epidemiologic Survey on Alcohol and ...
... The Arthritis Foundation announces the 2008 winners of the ... The recipients, Dr. Gerard Karsenty of the Columbia University ... University received the award for their continued research advancements ... , Dr. Karsenty is recognized for his research in ...
... 1 Senetek PLC,(OTC Bulletin Board: SNKTY), a life ... the science of healthy aging,announced today that Dynamics Group ... and research with offices in Zurich,Bern and Geneva has ... The Research Report, available ...
Cached Medicine News:Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 2Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 3Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 4Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 5Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 6Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 7Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 8Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 9Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 10Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 11Health News:The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders 2Health News:Few Young Adults Seek Treatment for Psych Disorders 2
(Date:9/17/2014)...  Neuraltus Pharmaceuticals, Inc. announced today that promising efficacy ... NP001 for the treatment of amyotrophic lateral sclerosis (ALS, ... today in an oral presentation at the inaugural ... in Bloomington, Minnesota , September 17-19, ... a high dose of NP001 (2mg/kg) was associated with ...
(Date:9/17/2014)... , Sept. 17 2014 IBM (NYSE: ... is using IBM technical computing and storage technology ... cancer patients. These services deliver critically important information ... each patient,s unique cancer, which could lead to ... healthcare system in general. Today, optimal ...
(Date:9/17/2014)... Switzerland , September 17, 2014 /PRNewswire/ ... , is proud to congratulate Biocartis commitment in ... Diagnostics is a long-time investor in Biocartis as ... ™ Biocartis, fully automated, real-time PCR based ... fast and easy access to clinical molecular diagnostic ...
Breaking Medicine Technology:Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 2Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 4Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument 2
... N.J. , March 11 Bayer HealthCare ... been granted by the U.S. Food and Drug Administration ... of pulmonary infection due to Pseudomonas aeruginosa in cystic ... granted by the European Medicines Agency. Ciprofloxacin DPI is ...
... DETROIT , March 11 Caraco Pharmaceutical ... oxaliplatin injections. These 50mg and 100mg oxaliplatin injections, which ... from the US Food and Drug Administration (FDA) for ... an anticancer used in the treatment of colon and ...
Cached Medicine Technology:FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 2FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 3FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 4FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 5FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 6FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 7FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 8Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R) 2Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R) 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: